These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 280254)

  • 21. Effects of reserpine, alpha-methyl-p-tyrosine, p-chlorophenylalanine and 5,7-dihydroxytryptamine on the hippocampal kindling effect in rats.
    Araki H; Aihara H; Watanabe S; Yamamoto T; Ueki S
    Jpn J Pharmacol; 1983 Dec; 33(6):1177-82. PubMed ID: 6230476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of neonatal administration of 5,7-dihydroxytryptamine on locomotor activity.
    Lucot JB; Seiden LS
    Psychopharmacology (Berl); 1982; 77(2):114-6. PubMed ID: 6812128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potentiation in phencyclidine-induced serotonin-mediated behaviors after intracerebroventricular administration of 5,7-dihydroxytryptamine in rats.
    Nabeshima T; Yamaguchi K; Ishikawa K; Furukawa H; Kameyama T
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1139-46. PubMed ID: 2826756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased behavioural response to 5-methoxy-N,N-dimethyltryptamine but not to RU-24969 after intraventricular 5,7-dihydroxytryptamine administration.
    Nisbet AP; Marsden CA
    Eur J Pharmacol; 1984 Sep; 104(1-2):177-80. PubMed ID: 6499914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of adult or neonatal treatment with 6-hydroxydopamine or 5,7-dihydroxytryptamine on locomotor activity, monoamine levels, and response to caffeine.
    Erinoff L; Snodgrass SR
    Pharmacol Biochem Behav; 1986 Apr; 24(4):1039-45. PubMed ID: 3086901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical and behavioral alterations in developing rats treated with 5,7-dihydroxytryptamine.
    Breese GR; Vogel RA; Mueller RA
    J Pharmacol Exp Ther; 1978 Jun; 205(3):587-95. PubMed ID: 307057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioral and prolactin responses to 5-hydroxytryptophan in rats treated during development with 5,7-dihydroxytryptamine.
    Breese GR; Vogel RA; Kuhn CM; Mailman RB; Mueller RA; Schanberg SM
    Brain Res; 1978 Oct; 155(2):263-75. PubMed ID: 308387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1-5-Hydroxytryptophan-induced flat body posture in the rat: antagonism by ritanserin and potentiation after 5,7-dihydroxytryptamine.
    Colpaert FC; Koek W; Lategan A
    Eur J Pharmacol; 1989 Oct; 169(1):175-8. PubMed ID: 2513211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of 5,7-dihydroxytryptamine on the concentration of individual proteins in different areas of the rat brain.
    Heydorn WE; Creed GJ; Nguyen KQ; Jacobowitz DM
    Brain Res; 1986 Mar; 368(1):193-6. PubMed ID: 3006866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of 5,7-dihydroxytryptamine administered at birth on the development of brain monoamines.
    Lytle LD; Jacoby JH; Nelson MF; Baumgarten HG
    Life Sci; 1974 Sep; 15(6):1203-17. PubMed ID: 4549961
    [No Abstract]   [Full Text] [Related]  

  • 31. Reduction of substance P levels in the ventral cervical spinal cord of the rat after intracisternal 5,7-dihydroxytryptamine injection.
    Singer E; Sperk G; Placheta P; Leeman SE
    Brain Res; 1979 Oct; 174(2):362-5. PubMed ID: 487135
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of central 5,7-dihydroxytryptamine on the medical hypothalamic syndrome in rats.
    Coscina DV
    Ann N Y Acad Sci; 1978 Jun; 305():627-44. PubMed ID: 280259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential effects of p-chlorophenylalanine and 5,7-dihydroxytryptamine on feeding in rats.
    Hoebel BG; Zemlan FP; Trulson ME; MacKenzie RG; DuCret RP; Norelli C
    Ann N Y Acad Sci; 1978 Jun; 305():590-4. PubMed ID: 152082
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of 5,7-dihydroxytryptamine and p-chlorophenylalanine on temperature regulation in rats.
    Lin MT; Pang IH; Chern YF; Chern SI
    J Pharm Pharmacol; 1978 Nov; 30(11):723-5. PubMed ID: 31440
    [No Abstract]   [Full Text] [Related]  

  • 35. Interaction of 5,6- and 5,7-dihydroxytryptamine with tissue monoamine oxidase.
    Klemm HP; Baumgarten HG
    Ann N Y Acad Sci; 1978 Jun; 305():36-56. PubMed ID: 280252
    [No Abstract]   [Full Text] [Related]  

  • 36. Enhancement of footshock-induced analgesia by spinal 5,7-dihydroxytryptamine lesions.
    Hutson PH; Tricklebank MD; Curzon G
    Brain Res; 1982 Apr; 237(2):367-72. PubMed ID: 7083000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of 5,7-dihydroxytryptamine lesions of the median and of the dorsal raphe nuclei on social interaction in the rat [proceedings].
    Collins GG; File SE; Hyde JR; Macleod NK
    Br J Pharmacol; 1979 May; 66(1):114P-115P. PubMed ID: 454910
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of body weight changes after selective serotonin depletion with 5,7-dihydroxytryptamine.
    Baez LA; Browning RA; Cusatis M
    Prog Neuropsychopharmacol; 1980; 4(2):123-7. PubMed ID: 7403347
    [No Abstract]   [Full Text] [Related]  

  • 39. Alterations in the neurocytotoxicity of 5,7-dihydroxytryptamine by pharmacologic agents in adult and developing rats.
    Breese GR; Mueller RA
    Ann N Y Acad Sci; 1978 Jun; 305():160-74. PubMed ID: 280248
    [No Abstract]   [Full Text] [Related]  

  • 40. Characteristics of central 5-HT receptors and their adaptive changes following intracerebral 5,7-dihydroxytryptamine administration in the rat.
    Nelson DL; Herbet A; Bourgoin S; Glowinski J; Hamon M
    Mol Pharmacol; 1978 Nov; 14(6):983-95. PubMed ID: 732817
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.